ARTICLE | Company News

Gilead, Cadila Pharmaceuticals, Cipla, Hetero Drugs, Mylan, Ranbaxy, SeQuent Scientific, Strides Arcolab deal

September 22, 2014 7:00 AM UTC

Gilead signed non-exclusive licensing agreements allowing seven generic manufacturers to produce and market its chronic HCV drugs sofosbuvir and sofosbuvir/ledipasvir in 91 developing countries. Gilead said the deals are part of the company's humanitarian program in the countries, where generic manufacturing is a "key component" in expanding access to the drugs. According to Gilead, the countries account for over 100 million people with HCV or 54% of the total globally infected population. Licensees will receive complete technology transfer of the Gilead manufacturing process, will be able to set their own price for the generics and will pay 7% royalties to Gilead. The agreements do not prevent the generics companies from manufacturing other chronic HCV drugs.

Last month, Gilead said it would make its branded version of Sovaldi sofosbuvir available in India and Egypt for about $900 for a 12-week course, which the company said is its standard low-income public pricing structure for the drug (see BioCentury, Aug. 11) ...